Cover Image

High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas

The role of high-dose chemotherapy (HDCT) with PBSCT in the treatment of bone and soft-tissue sarcomas is not established. In total, 27 patients (15 female, median age at TPL 30.6 years (range: 13-59)) were analyzed (Ewing sarcoma family n=8, osteosarcoma n=6, MPNST (malignant peripheral nerve sheat...

Full description

Saved in:
Bibliographic Details
Main Authors: Kasper, Bernd (Author) , Lehnert, T. (Author) , Bernd, Ludger (Author) , Mechtersheimer, Gunhild (Author) , Goldschmidt, Hartmut (Author) , Ho, Anthony Dick (Author) , Egerer, Gerlinde (Author)
Format: Article (Journal)
Language:English
Published: 31 May 2004
In: Bone marrow transplantation
Year: 2004, Volume: 34, Issue: 1, Pages: 37-41
ISSN:1476-5365
DOI:10.1038/sj.bmt.1704520
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.bmt.1704520
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/1704520
Get full text
Author Notes:B. Kasper, T. Lehnert, L. Bernd, G. Mechtersheimer, H. Goldschmidt, A.D. Ho and G. Egerer
Description
Summary:The role of high-dose chemotherapy (HDCT) with PBSCT in the treatment of bone and soft-tissue sarcomas is not established. In total, 27 patients (15 female, median age at TPL 30.6 years (range: 13-59)) were analyzed (Ewing sarcoma family n=8, osteosarcoma n=6, MPNST (malignant peripheral nerve sheath tumor) n=4, synovial sarcoma n=3, liposarcoma n=2, leiomyosarcoma n=2, rhabdomyosarcoma n=1, meningosarcoma n=1). Following chemotherapy and surgery complete remission (CR) (n=9), partial remission (PR) (n=10), stable disease (SD) (n=2) and progressive disease (PD) (n=6) were reached prior HDCT. Different HDCT conditioning regimens were used. One patient died due to cardiac arrest after HDCT. Except hematologic side effects, no WHO grade III-IV complications were observed. Four patients died within 6 months due to PD, disease recurred in another seven patients and led to death, 15 patients are alive with/without disease. The median progression-free survival (PFS) is 12.0 months (range: 0-58), in nine CR patients median PFS is 25.8 months (range: 3-58). Although the role of HDCT in the treatment of sarcomas is not defined, a subgroup of patients who achieved CR before HDCT could benefit from this therapy.
Item Description:Gesehen am 03.12.2021
Physical Description:Online Resource
ISSN:1476-5365
DOI:10.1038/sj.bmt.1704520

Similar Items